

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT USE SEVERAL SHEETS IF NECESSARY	ATTY. DOCKET NO. 202.8	APPLICATION NO. 10/087,929
	APPLICANT Ahlem, et al.	
	FILING DATE 3/1/02	GROUP 1618 / 618

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
JS	3,787,453	1/22/74	Farenholtz	—	—		

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	PUB. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
JS	Alauddin, M, et al, Biological activity in steroids possessing nitrogen atoms: Part 1 Synthetic nitrogenous steroids, <i>J. Pharmacy Pharmacol.</i> , 14:325-349 1962
JS	Alauddin, M, et al, Biological activity in steroids possessing nitrogen atoms: Part 2 Steroidal alkaloids, <i>J. Pharmacy Pharmacol.</i> , 14:469-495 1962
JS	Martin-Smith, M, et al, Biological activity in steroids possessing nitrogen atoms: recent advances, <i>J. Pharmacy Pharmacol.</i> , 16:569-595 1964

EXAMINER JAMES M. SPEAR	DATE CONSIDERED 07-06-2005
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.8APPLICATION NO.
10/087,929SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Ahlem, et al.FILING DATE
3/1/02GROUP
1618-1618

USE SEVERAL SHEETS IF NECESSARY

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL	PUBLICATION NUMBER	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JS	2002/0019376 A1	Savage et al.			
JS	2004/0097406 A1	Ahlem et al.			
	2003/0113284 A1	Dalko et al.			
	2002/0091278 A1	Savage et al.			
	2003/0060425 A1	Ahlem et al.			
	2004/0116359 A1	Ahlem et al.			
	2004/0060425 A1	Ahlem et al.			
	2002/0187973 A1	Labrie			
	2004/0043973 A1	Ahlem et al.			
JS	2004/0082556 A1	Labrie et al.			
	2003/0083231 A1	Ahlem et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	PUB. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
JS	EP 0 576 915 B1	01/05/94	Europe				
JS	WO 99/08684	08/17/98	PET WO				
JS	WO 97/41867	11/13/97	PET WO				
JS	EP 0 576 914 A2	01/05/94	Europe				

EXAMINER

JAMES M. SPEAR

DATE CONSIDERED


07-06-2005

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.8APPLICATION NO.
10/087,929SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Ahlem, et al.FILING DATE
3/1/02GROUP
1615 / 618

USE SEVERAL SHEETS IF NECESSARY




INITIAL	OTHER DOCUMENTS INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
gs	Wheeler, O., et al, "Steroid derivatives of cysteamine and cysteine", <i>Canadian J of Chem</i> , Vol 47, pp 160-62 (1969)
↑	Kondziolka, D., et al, "Beneficial effects of the radioprotectant 21-aminosteroid U-74389G in a radiosurgery rat malignant glioma model", <i>Int. J. Rad. Onc. Biol. Phys.</i> , Vol 44 (1), pp. 179-84 (1999)
	Evens, R., et al, "Androgens and erythropoiesis", <i>J. Clin. Pharm.</i> , pp. 94-101 (1974)
	Sigg, H., et al, <i>Helvetica Chimica ACTA</i> , Vol. 39 (6), pp. 1507 - 1525 (1956)
	Mulder, et al., "Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men", <i>J. of Infectious Diseases</i> , 165, pp. 413-18 (1992)
	Clerici, et al., "A possible role for the cortisol/anticortisol imbalance in the progression of human immunodeficiency virus", <i>Psychoneuroendocrinology</i> 22 (Suppl 1), pp S27-S31 (1997)
	Rasmussen, K., et al, "Effects of dehydroepiandrosterone in immunosuppressed rats infected with cryptosporidium parvum", <i>J. Parasitol</i> , Vol. 79 (3), pp. 364-70 (1993)
	Loria, et al., "Androstenediol regulates systemic resistance against lethal infections in mice", <i>archives of Virology</i> , 127, pp. 105-15 (1992)
	Gidari, A., et al, "Cyproterone-mediated stimulation of δ -aminolevulinic acid synthetase in chick embryo liver cells", <i>Endocrinology</i> , 99, pp. 130-36 (1976)
	Morrow, D., et al, "The synthesis of 17 β -amino-17-isoprogesterone", <i>J Org Chem</i> , pp 579-87 (1965)
	Goldman, A., et al, "Inhibitors of human placental C ₁₉ and C ₂₁ 3 β -hydroxysteroid dehydrogenases", <i>Biochimica et Biophysica Acta</i> , 315, pp. 233-49 (1973)
	Padgett, et al., "In vitro potentiation of lymphocyte activation by dehydroepiandrosterone, androstenediol, and androstetriol", <i>J. of Immunology</i> , 153, pp. 1544-52 (1994)
	Moog, et al., "Oxysterols, but not cholesterol, inhibit human immunodeficiency virus replication in vitro", <i>Antiviral Chemistry & Chemotherapy</i> , pp. 9, pp. 491-96 (1998)
	Xia, P, et al, "Anti-AIDS agents. Part 36: 17-carboxylated steroids as potential anti-HIV agents", <i>Bioorganic & Medicinal Chem</i> , 7, pp. 1907-11 (1999)
	Daigle, J., et al., "Androstenediol antagonizes herpes simplex virus type 1-induced encephalitis through the augmentation of type 1 IFN production", <i>The J of Immunology</i> , pp. 3060 - 3066 (1998)
	Lafaye, P, et al., "The 7 α -hydroxysteroids produced in human tonsils enhance the immune response to tetanus toxoid and Bordetella pertussis antigens", <i>Biochimica et Biophysica Acta</i> , 1472, pp. 222 - 31 (1999)
	Fareidn, I., et al., "Transformation in vitro of [4- ¹⁴ C]-dehydroepiandrosterone into 7-oxygenated derivatives by normal human male and female skin tissue", <i>The J of Investigative Dermatology</i> , Vol. 52, No. 4, pp. 357 - 61 (1969)
↓	Davis, A., et al, "Sterocontrolled synthesis of cholic acid derivatives with N-protected 7 β -and/or 12 β -amino substituents", <i>Tetrahedron Letters</i> , Vol 33, No. 35, pp. 5111-12 (1992)
gs	Davis, M., et al, "Steroid amines. Part IV. 3,17-diaminoandrostane derivatives", <i>J Chem. Soc</i> , 11, pp. 1045 - 52 (1967)

EXAMINER JAMES M. SPEAR

DATE CONSIDERED 07-06-2005

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.8APPLICATION NO.
10/087,929SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Ahlem, et al.FILING DATE
3/1/02GROUP
1615 1618

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JS	6,667,299 B1	12/23/03	Ahlem et al.			
JS	3,631,033	12/28/71	Nathansohn et al.			
	3,264,326	08/02/66	Clark et al			
	4,424,218	01/03/84	Deraedt et al			
	6,046,185	04/04/00	Burgoyne et al			
	6,635,629 B2	10/21/03	Raymond et al			
	6,706,701 B1	03/16/04	Burgoyne et al			
	4,395,408	07/26/83	Torelli et al			
	5,292,730	03/08/94	Lardy			
	3,780,073	12/18/73	Shroff			
	4,118,488	10/03/78	Philippson et al			
	5,198,432	03/30/93	Fariss			
	5,292,730	03/08/94	Lardy			
	5,583,126	12/10/96	Daynes et al.			
	5,593,981	01/14/97	Labrie			
	5,885,997	03/23/99	Pauza et al			
	5,888,534	03/30/99	El-Rashidy et al			
JS	5,955,455	09/21/99	Labrie			
	5,739,136	04/14/98	Ellinwood, Jr., et al.			


U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL	PUBLICATION NUMBER	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

EXAMINER JAMES M. SPEAR

DATE CONSIDERED 07-06-2005

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.8APPLICATION NO.
10/087,929SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Ahlem, et al.FILING DATE
3/1/02GROUP
1615 1618

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	PUB. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
JS	WO 97/34871	09/25/97	PCT WO				
↑	WO 97/37662	03/19/97	PCT WO				
	WO 97/37664	10/16/97	PCT WO				
	WO 97/40062	03/26/97	PCT WO				
↓	WO 98/02450	07/11/97	PCT WO				
JS	WO 99/25333	11/19/97	PCT WO				

EXAMINER INITIAL	OTHER DOCUMENTS INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
JS	Jones, et al, "Steroids and Steroidases. 10. Studies on some potentially antitumor active androstane compounds containing C-17 nitrogen mustard functions", <i>J of Med Chem</i> , Vol 14 (9), pp. 827-33 (1971)
↑	Arth, G., et al., "Steroidal androgen biosynthesis inhibitors", <i>J of Med Chem</i> , Vol 14 (8), pp. 675-79 (1971)
	Yagishita, K., "Studies on antimicrobial activities and aminosteroids - II", <i>Bull. Coll. Agr. & Vet. Med., Nihon Univ.</i> , No. 28, pp. 8 - 17 (1971)
	Pettit, G., et al, "Structural biochemistry. IV. 3β-hydroxy-17β-(L-prolyl)amino-androst-5-ene", <i>Canadian J of Chem</i> , Vol. 45, pp. 501 - 07 (1967)
	Navarro, J., et al, "Androgen therapy for anemia in elderly uremic patients", <i>Intl Urology and Nephrology</i> , 32, pp. 549-57 (2001)
	Whitnall, M., et al, "In vivo radioprotection by 5-androstenediol: Stimulation of the innate immune system", <i>Radiation Research</i> , 156, pp. 283-93 (2001)
	Byron, J., "Nature of the erythropoietin-independent response of CFU-S to steroids", <i>Exp. Hematol.</i> , 8, pp. 160-67 (1980)
	Levere, R., et al, "Steroid metabolites and the control of hemoglobin synthesis", <i>Bull. NY Acad. Med</i> , Vol. 50 (5), pp. 563-75 (1974)
	Fisher, J., et al, "Androgens and erythropoiesis", <i>Israel J. Med. Sci.</i> , 7, pp. 892-900 (1971)
	Nema, S., et al, "Excipients and their use in injectable products", <i>PDA J of Pharm Sci & Tech</i> , Vol. 51(4), pp. 166-171 (1997)
↓	Ben-Nathan, et al, "Dehydroepiandrosterone protects mice inoculated with west nile virus and exposed to cold stress", <i>J. Med. Virol.</i> , 38, pp. 159-66 (1992)
JS	Carr, D., "Increased levels of IFN-γ in the trigeminal ganglion correlate with protection against HSV-1-induced encephalitis following subcutaneous administration with androstenediol", <i>J. of Neuroimmunology</i> , 89, pp. 160-87 (1998)

EXAMINER	JAMES M. SPEAR	DATE CONSIDERED	07-06-2005
----------	----------------	-----------------	------------

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.8APPLICATION NO.
10/087,929SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

USE SEVERAL SHEETS IF NECESSARY

APPLICANT
Ahlem, et al.FILING DATE
3/1/02GROUP
1616

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JS	4,412,953	11/01/83	Winters	1	1	
↑	3,155,690	11/03/64	Cole	1	1	
↓	3,187,022	06/01/65	Morrow	1	1	
JS	3,137,710	05/16/64	de Ruggieri	1	1	

U.S. PATENT APPLICATION DOCUMENTS

EXAMINER INITIAL	DOCUMENT SERIAL NUMBER	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	PUB. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
JS	Ben-Nathan, D. "Protection by dehydroepiandrosterone in mice infected with viral encephalitis", <i>Arch. Virol.</i> , Vol 120 (3-4), pp. 263-71 (1991)
↑	Rasmussen, K., et al, "Effects of dehydroepiandrosterone in immunosuppressed adult mice infected with cryptosporidium parvum", <i>J. Parasitol.</i> , Vol. 81 (3), pp. 429-33 (1995)
↓	Woods, M., et al, "Treatment of aged mice with dehydroepiandrosterone provides an adjuvant effect in the immunization with recombinant hepatitis B surface antigen", <i>J. Immunol.</i> , Vol. 150 (8)(2), pp. 77a (1993)
JS	Flouret, G., et al, "17-Aminoacylamido steroid antidepressants", <i>J of Medicinal Chem.</i> , 1972, Vol. 15 (12), pp. 1281-83 (1972)
	Stickney, D., et al, "HE2100 and HE3204 protect rhesus macaques from chemotherapy or radiation induced myelosuppression", 40 th Annual Meeting American Society of Clinical Oncology, <i>Proceedings of ASCO</i> (poster and abstract 6668), Vol. 23, pp. 597 (2004)

EXAMINER JAMES M. SPEAR

DATE CONSIDERED 07-07-2005

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.


 FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.8	APPLICATION NO. 10/087,929
	APPLICANT Ahlem, et al.	
	FILING DATE 3/1/02	GROUP 1616 1618

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
JS	2,531,441	11/28/50	Julian et al.			
JS	2,561,378	7/24/51	Julian et al.			
JS	2,566,336	9/4/51	Julian et al.			
JS	2,705,238	3/29/55	Julian et al.			
JS	3,001,988	9/26/61	Nysted			
JS	3,004,968	10/17/61	Jeger et al.			
JS	3,026,318	3/20/62	Hewett			
JS	3,080,360	3/5/63	Pappo			
JS	3,153,063	10/13/64	Ruggieri et al.			
JS	3,189,597	6/15/65	MacPhillamy et al.			
JS	4,263,290	4/21/81	Nedelec et al.			
JS	4,292,251	9/29/81	Overbeek			
JS	4,310,523	1/12/82	Neumann			
JS	4,329,296	5/11/82	Tax			
JS	4,330,539	5/18/82	Sleigh et al.			
JS	4,424,218	1/3/84	Deraedt et al.			
JS	4,602,008	7/22/86	Krsek			
JS	4,898,694	2/6/90	Schwartz et al.			
JS	4,956,355	9/11/90	Prendergast			
JS	5,001,119	3/19/91	Schwartz et al.			
JS	5,028,631	7/2/91	Schwartz et al.			
JS	5,077,284	12/31/91	Loria et al.			
JS	5,145,874	9/8/92	Johnson et al.			
JS	5,175,154	12/29/92	Schwartz et al.			
JS	5,206,008	4/27/93	Loria			
JS	5,372,996	12/13/94	Labrie			
JS	5,387,583	2/7/95	Loria			

EXAMINER	JAMES M. SPEAR	DATE CONSIDERED	07-06-2005
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.8APPLICATION NO.
10/087,929INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Ahlem, et al.FILING DATE
3/1/02GROUP
~~1616~~ / 618


U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
gs	5,206,008	4/27/93	Loria			
↑	5,407,684	4/18/95	Loria et al.			
	5,424,463	6/3/95	Lardy			
	5,461,042	10/24/95	Loria			
	5,478,566	12/26/95	Loria			
	5,489,581	2/6/96	Daynes et al.			
	5,494,899	2/27/96	Kincade et al.			
	5,532,230	7/2/96	Daynes et al.			
	5,583,126	12/10/96	Daynes et al.			
	5,585,371	12/17/96	Lardy			
	5,599,806	2/4/97	Cerri et al.			
	5,641,768	6/24/97	Loria			
	5,686,438	11/11/97	Daynes et al.			
	5,696,106	12/9/97	Schwartz et al.			
	5,705,662	1/6/98	Cerri et al.			
	5,728,688	3/17/98	Labrie			
	5,763,433	6/9/98	Morfin			
	5,776,923	7/7/98	Labrie			
	5,811,418	9/22/98	Daynes et al.			
	5,824,668	10/20/98	Rubinfeld et al.			
	5,837,269	11/17/98	Daynes et al.			
	5,846,963	12/8/98	Araneo et al.			
	5,908,833	6/1/99	Brattsand et al.			
	5,912,240	6/15/99	Loria			
✓	5,977,095	11/2/99	Araneo et al.			
gs	6,013,642	1/11/00	Foulkes et al.			

EXAMINER JAMES M. SPEAR

DATE CONSIDERED 07-06-2005

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.8	APPLICATION NO. 10/087,929
		APPLICANT Ahlem, et al.	
		FILING DATE 3/1/02	GROUP 1616 1618

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
JS	6,395,722	5/28/02	Gilat			
JS	6,667,299 B1	12/23/03	Ahlem et al.			

U.S. PATENT APPLICATION DOCUMENTS


EXAMINER INITIAL	DOCUMENT SERIAL NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	09/820,483	Ahlem et al.			
	10/087,929	Ahlem et al.			
	10/166,423	Labrie			8/11/99
	10/319,356	Ahlem, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	PUB. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
JS	GB 2 057 448	4/1/81	United Kingdom				
↑	WO 97/13500	4/17/97	PCT WO				
	WO 97/17992	5/22/97	PCT WO				
	WO 97/48401	12/24/97	PCT WO				
	WO 00/56757	9/28/00	PCT WO				
↓	WO 01/30802	5/3/01	PCT WO				
JS	WO 01/42273	6/14/01	PCT WO				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
JS	Araghi-Niknam, et al, Cytokine dysregulation and increased oxidation is prevented by dehydroepiandrosterone in mice infected with murine leukemia retrovirus, <i>Proc. Soc. Exp. Biol. Med.</i> 216, pages 386-391 (1997)

EXAMINER	JAMES M. SPEAR	DATE CONSIDERED	07-06-2005
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE REVERSE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.8	APPLICATION NO. 10/087,929
	APPLICANT Ahlem, et al.	
	FILING DATE 3/1/02	GROUP 1610 1618

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
JS	Araghi-Niknam, et al, Modulation of immune dysfunction during murine leukemia retrovirus infection of old mice by dehydroepiandrosterone sulfate (DHEAS), <i>Immunology</i> , 90, pages 344-349 (1997)
↑	Bebo, et al, Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells, <i>J. Immunology</i> , 162, pp. 35-40, (1999)
	Henderson, et al, Dehydroepiandrosterone and 16.alpha.-bromoeplandrosterone: Inhibitors of Epstein-Barr virus induced transformation of human lymphocytes, <i>Carcinogenesis</i> , vol. 2, no. 7, pages 683-686 (1981)
	Hernandez-Pando, et al, The effects of androstenediol and ehydroepiandrosterone on the course and cytokine profile of tuberculosis in BALB/c mice, <i>Immunology</i> , 95, pages 234-241 (1998)
	Inserra, et al, Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice, <i>Proc. Soc. Exp. Biol. Med.</i> , 218, pages 76-82 (1998)
	Kang, et al, Dehydroepiandrosterone and beta-endorphin enhance IL-12 gene expression, <i>Chemical Abstracts</i> , vol. 126, no. 9, 399-404 (1997)
	Manz, et al, Methyl 17.beta.-carboxyester derivatives of natural and synthetic glucocorticoids: correlation between receptor binding and inhibition of in vitro phytohaemagglutinin-induced lymphocyte blastogenesis, <i>J. Clin. Chem. Clin. Biochem</i> , 21, 69-75 (1983)
↓	Yang et al, Inhibition of HIV-1 Latency Reactivation by Dehydroepiandrosterone (DHEA) and an Analog of DHEA, <i>Aids Research and Human Retroviruses</i> , Vol. 9, no 8, 747-754, 1993
JS	Zhang, et al, Prevention of immune dysfunction and vitamin E loss by dehydroepiandrosterone and melatonin supplementation during murine retrovirus infection, <i>Immunology</i> , 96, 291-297 (1999)

EXAMINER* JAMES M. SPEAR	DATE CONSIDERED 07-06-2005
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.8


APPLICATION NO.

10/087,929

10/087,929

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Ahlem, et al.FILING DATE
3/1/02GROUP
1610

USE SEVERAL SHEETS IF NECESSARY



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JS	4,507,289	3/26/85	Coleman et al.			
JS	4,701,450	10/20/87	Kelder et al.			
	5,183,815	2/2/93	Saari et al.			
	5,527,789	6/18/96	Nyce			
	5,660,835	8/26/97	Nyce			
	5,681,964	10/28/97	Ashton, et al.			
	5,686,436	11/11/97	Van Dyke			
	5,744,462	4/28/98	Schwartz, et al			
	5,753,237	5/19/98	Daynes, et al			
	5,827,841	10/27/98	Daynes et al.			
	5,859,000	1/12/99	Dowell, et al			
	5,919,465	7/6/99	Daynes et al.			
	6,087,351	11/2/99	Nyce			
JS	6,286,515	7/31/01	Schneider et al.			
JS	6,667,299	12/23/03	Ahlem et al.			3/16/00

U.S. PATENT APPLICATION DOCUMENTS

EXAMINER INITIAL	DOCUMENT SERIAL NUMBER	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

EXAMINER


JAMES M. SPEAR

DATE CONSIDERED

07-06-2005

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.


FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.8	APPLICATION NO. 10/082,929 10/087,929
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Ahlem, et al.	
USE SEVERAL SHEETS IF NECESSARY		FILING DATE 3/1/02	GROUP 1616



FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL	DOCUMENT NUMBER	PUB. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
						YES	NO	
JS ↑ ↓ JS	DE 196 18 778 A1	5/10/96	Germany				X	
	EP 0 133 995	3/13/85	Europe					
	EP 0 289 327	11/2/88	Europe					
	EP 0 429 187 B1	1/5/94	Europe					
	EP 0 494 224 B1	5/10/00	Europe					
	930811 A1	5/3/95	Ireland					
	930590 A1	2/8/95	Ireland					
	950377 A1	11/27/96	Ireland					
	WO 97/38695	10/23/97	PET WO					
	WO 98/47516	10/29/98	PET WO					
	WO 99/52532	10/21/99	PET WO					

EXAMINER INITIAL	OTHER DOCUMENTS INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
JS	Abou-Gharbia, et al., Epiandrosterone- and Dehydroepiandrosterone-3 β -alkanesulfonates as Inhibitors of Mouse Glucose-6-phosphate Dehydrogenase Activity, <i>Journal of Pharmaceutical Sciences</i> , Vol. 73, No. 11, pp. 1643-1645 1984
↑	Abou-Gharbia, et al., Synthesis of Dehydroepiandrosterone Sulfatide and 16 α -Halogenated Steroids, <i>Journal of Pharmaceutical Sciences</i> , Vol. 70, No. 10, pp. 1154-1157 1981
	Adams, et al., Adrenal dehydroepiandrosterone and human mammary cancer, <i>Cancer Res.</i> 38:4036-4040 1978
	Belovsky, et al, Inhibition of glucose-6-phosphate dehydrogenase by steroids VIII: Effects of synthetic C ₁₉ - and C ₂₀ -steroids upon placental glucose-6-phosphate dehydrogenase, <i>J. Steroid Biochem.</i> , 5:697-700 1974
	Dale, et al, Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone, <i>J. Clin. Invest.</i> , 56:808-813 1975
	Deinard, et al., A study of steroid-induced granulocytosis in a patient with chronic benign neutropenia of childhood, <i>Brit. J. Hematol.</i> , 28:333-345 1974
	Evans, et al., The erythropoietic response to anabolic therapy in patients receiving radiotherapy, <i>J. Clin. Pharmacol.</i> , 12:101-104 1972
↓	Francis, et al., The effect of androstanes on granulopoiesis <i>in vitro</i> and <i>in vivo</i> , <i>British J. Hematol.</i> , 36:501-510 1977
JS	Frey-Wettstein, et al., Testosterone-induced depletion of thymus and marrow lymphocytes as related to lymphopoiesis and hematopoiesis, <i>Blood</i> , 35:257-271 1970


EXAMINER	JAMES M. SPEAR	DATE CONSIDERED	07-06-2005
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 	ATTY. DOCKET NO. 202.8	APPLICATION NO. 10/082,929 10/087,929
	SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	
	APPLICANT Ahlem, et al.	FILING DATE 3/1/02

EXAMINER INITIAL	OTHER DOCUMENTS INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
JS	Gallicchio, et al., Regeneration of murine megakaryocytopoiesis and the hematopoietic inductive microenvironment after sublethal whole body irradiation by treatment with an anabolic steroid, <i>Acta Hematol.</i> , 73:80-85 1985
↑	Gorshein, et al., Tissue culture of bone marrow. V. Effect of 5β(H) steroids and cyclic AMP on heme synthesis, <i>Am. J. Physiol.</i> , 228:1024-1028 1975
	Chang, et al, Suppression of Δ5-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells, <i>Proc. Natl. Acad. Sci. U.S.A.</i> 96:11173-11177 1999
	Horn, A comparison of two androgenic hormones as leukopoietic agents in irradiated rats, <i>Oncology</i> , 26:16-24 1972
	Horn, Leucopoietic properties of four different androgenic hormones in irradiated rats, <i>Scand. J. Hematol.</i> , 8:470-475 1971
	Horn, The effect of androgenic hormones on bone marrow of rats receiving chemotherapy, <i>Oncology</i> , 25:512-519 1971
	Horn, et al., The effect of androgens on erythroid and granulocytic marrow recovery in the irradiated rat, <i>Acta Hematol.</i> , 48:300-305 1972
	Johnson, et al, Active site-directed inhibition of rabbit cytochrome P-450 1 by amino-substituted steroids, <i>J. Biol. Chem.</i> , 261:10204-10209 1986
	Kabara, et al, Structure-function activity of azasterols and nitrogen-containing steroids, <i>Lipids</i> , 11:755-762 1976
	Kennedy, Stimulation of hematopoiesis by androgenic hormones, <i>Geriatrics</i> , 20:808-815 1965
	Kellis, et al, Amino-steroids as inhibitors and probes of the active site of cytochrome P-450sc. Effects on the enzyme from different sources, <i>J. Steroid Biochem.</i> , 20:671-676 1984
	Lardy, et al., Ergosteroids. II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosterone, <i>Steroids</i> 63:158-165 1998
	Loria, et al., Regulation of the immune response by dehydroepiandrosterone and its metabolites, <i>J. Endocrinol.</i> 150 Suppl.: S209-220 1996
	Lucas, et al., Some hypotensive amino steroid glycosides, <i>J. Amer. Chem. Soc.</i> , 82:5688-5693 1960
	Marwa, et al, Ergosteroids IV: synthesis and biological activity of steroid glucuronosides, ethers, and alkylcarbonates, <i>Steroids</i> . 66:581-595 2001
	Michel et al., New azasteroidal antifungal antibiotics from <i>Geotrichum Flavobrunneum</i> : II. Isolation and characterization, <i>J. Antibiotics</i> , 28:102-111 1975
	Moores et al., Stimulation of erythropoietin by androgen in the human, <i>Scand. J. Hematol.</i> , 5:415-424 1968
	Norbiato, G., et al., Glucocorticoid Resistance and the Immune Function in the Immunodeficiency Syndrome, <i>Ann. N.Y. Acad. Sci.</i> , Vol. 840, pp. 835-847 1998
	Norbiato, G., et al., Glucocorticoids and the Immune Function in the Human Immunodeficiency Virus Infection: A Study in Hypercortisolemic and Cortisol-Resistant Patients, <i>Journal of Clinical Endocrinology and Metabolism</i> , Vol. 82, No. 10, pp. 3260-3263 1997
	Norbiato, G, et al., Glucocorticoids and Interferon-α in the acquired immunodeficiency syndrome, <i>Journal of Clinical and Metabolism</i> , Vol. 81, No. 7, 1996
	Pashko, L., et al., Inhibition of DNA synthesis in mouse epidermis and breast epithelium by dehydroepiandrosterone and related steroids, <i>Carcinogenesis</i> , 2:717-721 1981
	Pittaway, Inhibition of testosterone synthesis in the canine testis in vitro, <i>Contraception</i> , 27:431-436 1983
↓	Rawbone, et al., Anabolic steroids and bone marrow toxicity during therapy with methotrexate, <i>British J. Cancer</i> , 26:395-401 1972
JS	Rosenblum, et al., Androgenic hormones and human granulopoiesis <i>in vitro</i> , <i>Blood</i> , 43:351-356 1974

EXAMINER	JAMES M. SPEAR	DATE CONSIDERED	07-06-2005
----------	----------------	-----------------	------------

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.8	APPLICATION NO. 10/082,929 10/087,929
 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT USE SEVERAL SHEETS IF NECESSARY		APPLICANT Ahlem, et al.	
		FILING DATE 3/1/02	GROUP 1610

EXAMINER INITIAL	OTHER DOCUMENTS INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
JS	Ruzicka, et al., Sex hormones XII, About amines of the androstene group, <i>Helv. Chim. ACTA</i> , 19:107-108 1936 translation of first four paragraphs at page 107
↑	Shearer, G., Commentary: Th1/Th2 changes in aging, <i>Mechanisms of Ageing and Development</i> , 94:1-5 1997
	Shearer, et al., Cytokine Profiles in HIV Type 1 Disease and Protection, <i>AIDS Research and Human Retroviruses</i> , 14:S-14-S-152 1998
	Sheets et al., Active site-directed inhibitors of cytochrome P-450 _{sc} . Structural and mechanistic implications of a side chain-substituted series of amino-steroids, <i>J. Biol. Chem.</i> 258:11446-11452 1983
	Sheets et al., Proximity of the substrate binding site and the heme-iron catalytic site in cytochrome P-450 _{sc} , <i>Proc. Natl. Acad. Sci. USA</i> 79:5773-5777 1982
	Singer, et al., Steroids and hematopoiesis. III. The response of granulocytic and erythroid colony-forming cells to steroids of different classes, <i>Blood</i> , 48:855-864 1976
	Singer, et al., Steroids and hematopoiesis. I. The effect of steroids on in vitro erythroid colony growth: structure/activity relationships, <i>J. Cell. Physiol.</i> , 88:127-134 1976
	Udupa, et al., Stimulation of granulopoiesis by androgens without concomitant increase in the serum level of colony stimulating factor, <i>Exp. Hematol.</i> , 3:26-31 1975
	Udupa, et al., Acceleration of granulopoietic recovery by androgenic steroids in mice made neutropenic by cytotoxic drugs, <i>Cancer Res.</i> , 34:2517-2520 1974
	Vincze, et al., Steroids 54. Amino acylamidosteroids, <i>Steroids</i> , 61, 697-702 1996
	Weinstein, et al., Effects of testosterone metabolites and of anabolic androgens on the bone marrow and thymus in castrated female mice, <i>Immunopharmacology</i> , 5:239-250 1983
	Whitcomb, J. et al., Dehydroepiandrosterone and 16 α -Br-epiandrosterone inhibit 12-O-tetradecanoylphorbol-13-acetate stimulation of superoxide radical production by human polymorphonuclear leukocytes, <i>IRL Press Ltd., Oxford, England</i> , pp. 333-335 1984
	Whitnall, et al., Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice, <i>Int. J. Immunopharmacol.</i> , 22:1-14 2000
JS	Whitnall, et al., Androstenediol stimulates myelopoiesis but not lymphopoiesis in irradiated mice, <i>Blood.</i> , 90 Suppl. 1 part 1:175A 1997

EXAMINER JAMES M. SPEAR	DATE CONSIDERED 07-06-2005
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	